2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.135 (Poster) Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III: A Multi Center Study

PP01.135 (Poster) Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III: A Multi Center Study

Back to course

Pdf Summary

This study aimed to understand the outcomes and treatment patterns for patients with stage III unresectable non-small cell lung cancer (NSCLC) who experienced recurrence after receiving concurrent chemoradiation and consolidation immunotherapy. The study included patients from two academic medical centers who had received chemoradiation and at least 1 dose of consolidation immunotherapy.<br /><br />The results showed that recurrence after consolidation immunotherapy was common, with a median 1-year overall survival for patients with recurrence. This was shorter than the historical controls for patients newly diagnosed with stage IV NSCLC. The outcomes were poor regardless of the pattern of recurrence, whether it was local or distant metastatic.<br /><br />Subgroup analyses suggested that outcomes (both progression-free survival and overall survival) were numerically better for patients who experienced recurrence after 1 year from the start of durvalumab (the consolidation immunotherapy), but these findings were not statistically significant. This indicates that further prospective studies are needed to determine the optimal treatments for recurrence after stage III treatment.<br /><br />The study also provided information on patient characteristics, such as sex, age, smoking history, histology, Eastern Cooperative Oncology Group (ECOG) performance status, and PD-L1 expression levels. Additionally, the study analyzed subsequent systemic therapy options for patients with progressive disease after recurrence.<br /><br />In conclusion, this multi-center study sheds light on the outcomes and treatment patterns for patients with stage III unresectable NSCLC who experience recurrence after concurrent chemoradiation and consolidation immunotherapy. The findings highlight the need for further research to identify the most effective treatment options for recurrence in this population.

Asset Subtitle

Philip Young

Keywords

stage III unresectable non-small cell lung cancer

recurrence

concurrent chemoradiation

consolidation immunotherapy

overall survival

historical controls

local metastasis

distant metastasis

durvalumab

prospective studies